2008-12-29

Plasma Leptin Levels and Incidence of Heart Failure, Cardiovascular Disease, and Total Mortality in Elderly Individuals

Lieb, Wolfgang, Lisa M. Sullivan, Tamara B. Harris, Ronenn Roubenoff, Emelia J. Benjamin, Daniel Levy, Caroline S. Fox, Thomas J. Wang, Peter W. Wilson, William B. Kannel, Ramachandran S. Vasan. "Plasma Leptin Levels and Incidence of Heart Failure, Cardiovascular Disease, and Total Mortality in Elderly Individuals" Diabetes Care 32(4): 612-616. (2008)
https://hdl.handle.net/2144/2549

Boston University
Plasma Leptin Levels and Incidence of Heart Failure, Cardiovascular Disease, and Total Mortality in Elderly Individuals

WOLFGANG LIEB, MD
LISA M. SULLIVAN, PHD
TAMARA B. HARRIS, MD
RONEN ROUBENOFF, MD, MHS
EMELIA J. BENJAMIN, MD, SCM
DANIEL LEVY, MD
CAROLINE S. FOX, MD, MPH
THOMAS J. WANG, MD, MPH
PETER W. WILSON, MD
WILLIAM B. KANNEL, MD, MPH
RAMACHANDRAN S. VASAN, MD

OBJECTIVE — Obesity predisposes individuals to congestive heart failure (CHF) and cardiovascular disease (CVD). Leptin regulates energy homeostasis, is elevated in obesity, and influences ventricular and vascular remodeling. We tested the hypothesis that leptin levels are associated with greater risk of CHF, CVD, and mortality in elderly individuals.

RESEARCH DESIGN AND METHODS — We evaluated 818 elderly (mean age 79 years, 62% women) Framingham Study participants attending a routine examination at which plasma leptin was assayed.

RESULTS — Leptin levels were higher in women and strongly correlated with BMI (P < 0.0001). On follow-up (mean 8.0 years), 129 (of 775 free of CVD) participants developed CHF, 187 (of 532 free of CVD) experienced a first CVD event, and 391 individuals died. In multivariable Cox regression models adjusting for established risk factors, log-leptin was positively associated with incidence of CHF and CVD (hazard ratio [HR] per SD increment 1.26 [95% CI 1.03–1.55] and 1.28 [1.09–1.50], respectively). Additional adjustment for BMI nullified the association with CHF (0.97 [0.75–1.24]) but only modestly attenuated the relation to CVD incidence (1.23 [1.00–1.51], P = 0.052). We observed a nonlinear, U-shaped relation between log-leptin and mortality (P = 0.005 for quadratic term) with greater risk of death evident at both low and high leptin levels.

CONCLUSIONS — In our moderate-sized community-based elderly sample, higher circulating leptin levels were associated with a greater risk of CHF and CVD, but leptin did not provide incremental prognostic information beyond BMI. Additional investigations are warranted to elucidate the U-shaped relation of leptin to mortality.

Diabetes Care 32:612–616, 2009

Excess adiposity is a key risk factor for congestive heart failure (CHF) (1) and cardiovascular disease (CVD) (2), in part because it is a fundamental precursor of several vascular risk factors including high blood pressure, dyslipidemia, and impaired glucose homeostasis. Increased BMI is often used as a surrogate measure of excess adiposity. However, BMI reflects the combined mass of adipose and nonadipose tissue (including muscles and bones). Therefore, leptin, an anorexogenic hormone that is predominantly produced in adipose tissue, may be a better risk marker for CVD than current BMI.

Several lines of evidence indicate a putative role for leptin in cardiac (3) and vascular remodeling (4,5), although reports are divided on whether leptin has predominantly adverse or beneficial effects on the heart (6,7) and the vascular system (4,8,9). Likewise, clinical studies on the association with CVD have yielded inconsistent results (10,11).

Interestingly, previous studies suggested that leptin levels are not only determined by the current adipose tissue volume but also by the weight history of an individual (12). Leptin might, therefore, be a better marker of CVD risk than current BMI, particularly in normal-weight individuals with a history of obesity, who might have subclinical CVD (due to antecedent obesity). Conversely, because obesity is associated with relative leptin resistance that often persists after weight reduction, “current” leptin levels may misclassify the biological effects of leptin exposure, leaving BMI with a stronger association to CVD outcomes (relative to leptin).

On the basis of the clinical and experimental data summarized above, we hypothesized that leptin levels are associated with the incidence of CHF, CVD, and all-cause mortality in elderly individuals. We tested this hypothesis by relating leptin levels to the occurrence of CVD (including CHF) and death prospectively in a moderate-sized elderly community-based sample; we assessed specifically whether leptin levels offer incremental prognostic information over established risk factors and BMI. We also sought to examine the cross-sectional clinical correlates of leptin and evaluated whether leptin correlates with measures of past BMI (i.e., serves as an indicator of an individual’s weight history).

RESEARCH DESIGN AND METHODS — The design and the selection criteria of the Framingham Heart Study have been published elsewhere.

From the 1Framingham Heart Study, Framingham, Massachusetts; the 2Department of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, Massachusetts; the 3 Intramural Research Program, Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, Bethesda, Maryland; the 4Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts; the 5Whitaker Cardiovascular Institute, Preventive Medicine and Cardiology Sections, Boston University School of Medicine, Boston, Massachusetts; the 6The Center for Population Studies of the National Heart, Lung, and Blood Institute, Bethesda, Maryland; the 7Endocrinology Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; the 8Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; and 9Emory University School of Medicine, Atlanta, Georgia.

Corresponding author: Ramachandran S. Vasan, vasan@bu.edu.

Received 29 August 2008 and accepted 22 December 2008.

Published ahead of print at http://care.diabetesjournals.org on 29 December 2008. DOI: 10.2337/dc08-1506.

© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Leptin assay
At examination cycle 22, blood was drawn from nonfasting participants, usually between 1:00 and 2:00 p.m. Plasma leptin levels were measured using a commercial radioimmunoassay (Linco Research, St. Louis, MO). The interassay coefficient of variation ranged from 3.0 to 6.2%. The lower sensitivity limit was 0.5 ng/ml.

Definitions of outcome events
All Heart Study participants are under continuous surveillance for the incidence of CVD (including CHF) and death. Outcome events are adjudicated by a team of three physicians who review all relevant medical information, hospitalization records, and physician office visits using standardized criteria. A separate group consisting of neurologists reviews and adjudicates all suspected cerebrovascular events. Criteria for CVD have been published and include coronary heart disease (CHD) (recognized and unrecognized myocardial infarction, coronary insufficiency, angina, and CHD death), cerebrovascular disease (stroke and transient ischemic attack), intermittent claudication, and CHF (14). A diagnosis of CHF requires the presence of at least two major criteria or one major and two minor criteria in the absence of a condition that can explain the findings. The same definitions have been used in the Framingham Heart Study over the years.

In our primary analyses, we focused on three end points: incident CHF, CVD, and total mortality. In secondary analyses, we related leptin with incident “hard” CVD, a composite end point that includes fatal and nonfatal myocardial infarction, coronary insufficiency, stroke, or CHF.

Statistical analyses
Given a right-skewed distribution, leptin levels were logarithmically transformed. We evaluated the correlation of log-leptin with BMI measured at the index examination, in the decade preceding the examination and over the interval of 10–20 years preceding the index examination (average of available values for the respective decades). Next, we evaluated the clinical correlates of log-leptin using multivariable linear regression. Eligible covariates included age, sex, BMI, systolic and diastolic blood pressure, antihypertensive treatment, total-to-HDL cholesterol ratio, triglycerides, diabetes, smoking, and prevalent CVD.

Separate analyses were conducted for each of the three outcomes. Analysis demonstrated a striking sexual dimorphism in leptin levels, as reported previously (15). Therefore, we standardized log-leptin values separately within sex. We performed pooled sex analyses relating sex-standardized log-leptin to the incidence of outcome events because we did not observe effect modification by sex (P ≥ 0.75 for interactions for all three outcomes).

We evaluated the cumulative incidence of outcome events for leptin levels greater than or equal to versus less than the sex-specific median value. The assumption of proportionality of hazards was confirmed. We used Cox regression to relate log-leptin to each outcome. Two sets of models were evaluated: 1) with adjustment for established risk factors; and 2) with additional adjustment for BMI. We built models using this hierarchical schema because leptin is strongly correlated with BMI and also to assess the incremental information provided by leptin over BMI alone. Covariates in the first model evaluating CHF incidence and mortality included age, sex, total/HDL cholesterol, diabetes, systolic and diastolic blood pressure, antihypertensive treatment, current smoking, history of atrial fibrillation, and prevalent CVD. For analyses of CVD incidence, covariates were similar with the exception that participants with prevalent CVD were excluded. To gain insights into potential nonlinearity of associations between leptin and risk of outcomes, we examined generalized additive models using penalized splines.

We tested for effect modification by age, hypertension status, and obesity separately for each of the outcomes. In secondary analyses, we related leptin levels to incidence of a first hard CVD event on follow-up (covariates as noted above for analyses of CVD). In secondary analyses, we assessed the association of leptin with CHF, CVD, and mortality in individuals with and without a history of obesity (defined as BMI ≥30 kg/m² at any time in the 25 years preceding baseline examination cycle 22 at which leptin was assayed). P < 0.05 was used to indicate statistical significance.

RESULTS — The baseline characteristics of our elderly study sample are shown in Table 1. Three-fifths of the sample comprised women, and there was a high prevalence of antihypertensive treatment, diabetes, and CVD.

Clinical correlates of leptin including relations to antecedent BMI
Leptin was strongly correlated with BMI at the index examination (r = 0.67, P < 0.0001). More modest correlations were noted with BMI in the decade preceding the index examination (average of readings obtained 1–10 years before baseline; r = 0.60, P < 0.0001) and with BMI 10–20 years before baseline (r = 0.46, P < 0.0001). Of note, BMI at the index examination was more strongly correlated (relative to leptin) with BMI in the previous decade (r = 0.93, P < 0.0001) and in the prior 10–20-year period (r = 0.83, P < 0.0001).

In multivariable analyses evaluating the clinical correlates of log-leptin, BMI (partial R² = 0.26) and sex (partial R² = 0.28) were the strongest correlates. Women (median 17.4 [quartile 1, quartile 3: 10.6, 28.7]) had higher leptin levels than men (7.2 [4.5, 11.4]; P < 0.001), as noted earlier. Positive associations of leptin were also noted with the ratio of total-to-HDL cholesterol (Table 2). Although participants with diabetes (13.4 [7.9, 23.2]) had higher leptin levels in unadjusted analyses than participants without diabetes (12.6 [6.5, 22.4]), these differences were no longer statistically significant upon adjustment for BMI.
**Leptin and incident CHF, CVD, and mortality**

**Table 1—Baseline characteristics of the study sample**

| Characteristic | Value |
|---------------|-------|
| Clinical features |       |
| Women (%)     | 62.3  |
| Age (years)   | 79.0 ± 4.5 |
| Systolic blood pressure (mmHg) | 143 ± 21 |
| Diastolic blood pressure (mmHg) | 72 ± 11 |
| BMI (kg/m²)   | 26.8 ± 4.7 |
| Antihypertensive treatment (%) | 48.9 |
| Current smoking (%) | 8.3 |
| Diabetes (%)  | 27.4  |
| History of atrial fibrillation (%) | 10.6 |
| Prevalent heart failure (%) | 5.3 |
| History of CVD (%) | 35.0 |
| Biochemical features |       |
| Total-to-HDL cholesterol ratio (mg/dl) | 4.54 ± 1.51 |
| Leptin (ng/ml) | 12.8 (7.0, 22.7) |
| Log-leptin | 2.51 ± 0.81 |

Data are % for binary traits and means ± SD for continuous traits, except for leptin for which data are median (quartile 1, quartile 3). n = 818. Log, natural logarithmically transformed.

**Association of leptin levels with incidence of CHF**

During a mean follow-up of 8.5 years (range 0.2–10), 129 participants (73 women) developed CHF. Figure A1a (available in an online appendix at http://care.diabetesjournals.org/cgi/content/full/dc08-1596/DC1) shows that the cumulative incidence of CHF in individuals with leptin levels greater than or equal to the sex-specific median value was higher than in participants with levels below the median (log-rank P = 0.038). In multivariable models without BMI, leptin was positively associated with incident CHF (Table 3, model I). Figure A1b (available in an online appendix) displays the results of splines relating leptin to CHF risk: a continuous gradient of increasing CHF risk is noted without evidence of a threshold. However, the association of leptin with CHF risk was rendered nonsignificant after additional adjustment for BMI (Table 3, model I).

**Association of leptin with CVD and hard CVD**

During a mean follow-up of 7.8 years, 187 participants experienced a first CVD event (121 women). Figure A2a (available in an online appendix) shows a higher cumulative incidence of CVD events in individuals with leptin levels greater than or equal to the sex-specific median compared with participants with levels below the median (log-rank P = 0.0030). Leptin was associated with CVD incidence in a multivariable-adjusted model without BMI, a finding confirmed by analysis of splines (Fig. A2b, available in an online appendix). However, the relations were attenuated, becoming borderline statistically significant, upon adjustment for BMI (Table 3, model II).

In secondary analyses, leptin levels were also associated with hard CVD events (141 events in, on average, 8.3 years of follow-up) in multivariable-adjusted models without BMI (hazard ratio [HR] 1.26 [95% CI 1.04–1.52], P = 0.016). However, this association was rendered statistically non-significant upon additional adjustment for BMI (1.05 [0.83–1.33], P = 0.70).

Based on the width of the confidence intervals presented in Table 3, we can exclude (with 95% confidence) a >24% increase in the hazard of developing CHF and a >51% increase in the hazard of developing CVD per 1 SD increase in sex-standardized log-leptin in models assessing incremental contribution of leptin levels over BMI. More modest incremental associations (over BMI) of leptin with CHF and CVD outcomes would require analyses of much larger samples.

**Association of leptin levels with total mortality**

During a mean follow-up of 8.0 years, 391 participants (217 women) died. The cumulative incidence of death in participants did not seem to differ for participants with leptin levels more than or equal to versus less than the sex-specific median (log-rank P = 0.55) (Fig. A3a, available in an online appendix). Overall, leptin levels were not related to total mortality in multivariable models without (HR 1.00 [95% CI 0.89–1.12]) and with (0.97 [0.84–1.12]) adjustment for BMI. Analyses of splines revealed a U-shaped relation of log-leptin levels with mortality (Fig. A3b, available in an online appendix). Adding log-leptin squared into the model confirmed a significant association with log-leptin squared and mortality in multivariable models without (P = 0.002) and with (P = 0.005) adjustment for BMI. Given the U-shaped relation of log-leptin and mortality, we repeated the analysis excluding participants who died within the first year of follow-up (n = 19) to exclude the possibility that the association between lower leptin levels and mortality may be due to reverse causality (i.e., comorbidity leads to low leptin levels and is associated with higher mortality). Our results were essentially unchanged in these analyses (P = 0.0099 for log-leptin squared).

To further explore the contributions of cardiovascular versus noncardiovascular mortality to the U-shaped relations, in post hoc analyses we examined the two outcomes separately. On follow-up, 133 participants died of CVD and 258 of non-CVD. In multivariable-adjusted models including BMI, log-leptin squared was not related to CVD death (P = 0.70) but was associated with non-CVD death (P = 0.006).

**Table 2—Clinical determinants of log-leptin in elderly individuals**

| Variable                  | β    | SE    | Partial R² | P value |
|---------------------------|------|-------|------------|---------|
| Age                       | −0.007 | 0.004 | 0.002      | 0.071   |
| Male sex                  | −0.918 | 0.037 | 0.282      | <0.0001 |
| BMI                       | 0.094  | 0.004 | 0.257      | <0.0001 |
| Total cholesterol-to-HDL ratio | 0.042  | 0.012 | 0.005      | 0.001   |
| History of CVD            | 0.070  | 0.038 | 0.002      | 0.067   |
| Antihypertensive treatment | 0.064  | 0.036 | 0.001      | 0.080   |
| Current smoking           | −0.119 | 0.065 | 0.002      | 0.067   |

The regression coefficient indicates the increase in log-leptin per 1-unit increment in the predictor variable, meaning that, e.g., a 1-unit increment in BMI leads to a 0.094-unit increase in log-leptin (1.10 in nanograms per milliliter).
CONCLUSIONS

Secondary analyses
In exploratory analyses, associations of leptin with CHF and CVD were similar in participants with (n = 270 [33%]) and without (data not shown) a history of obesity. Likewise, a U-shaped association of leptin with mortality was observed in both subgroups.

Clinical correlates of leptin: comparison with the published literature
Our observations that BMI and female sex are principal determinants of leptin are consistent with findings in the literature (15,16). Women have greater body fat than men, and adipose tissue is a major source of leptin, which might explain the higher leptin levels in women. It has been suggested that leptin captures the weight history of individuals (12). We observed that leptin correlated with the mean BMI averaged over 0–10 and 10–20 years before the baseline examination. However, leptin was not as strongly correlated with past weight history as current BMI.

Association of leptin levels with CHF
In previous cross-sectional studies, increased levels of leptin and its receptor were reported in patients with CHF (17,18). Furthermore, increasing evidence indicates that leptin may modulate cardiac remodeling (3). In experimental studies, leptin exhibited a dose-dependent inhibition of myocyte shortening in ventricular myocytes (19). Likewise, leptin had a direct hypertrophic effect on cultured myocytes (6). However, some investigators have highlighted an antihypertrophic effect of leptin (7,20). These findings suggest that leptin has a cardioprotective role and that increased levels in patients with cardiac disease might be a response to cardiac injury or failure rather than being directly causal.

It is difficult to conclude from the positive relations of leptin to CHF incidence that leptin is an important mediator of disease (1) or whether higher levels are a compensatory response to underlying cardiac remodeling. In our analysis, leptin did not add incremental predictive information beyond current BMI.

Association of leptin levels with CVD and mortality
Clinical data on the association of leptin with CVD are inconsistent. In some studies, leptin was associated with incident myocardial infarction or coronary artery disease (10,21), whereas other investigators did not find an association between leptin and CHD (11).

Experimental data on leptin and vascular remodeling are likewise controversial, with some studies suggesting an atherogenic effect (4,5) and other reports indicating a vasculoprotective effect (9,22). In our analyses, leptin was positively associated with CVD only in models that did not include adjustment for BMI. These data are consistent with the concept that leptin may be an important mediator of obesity-associated CVD risk, but it offers no incremental prognostic information over BMI.

We observed a U-shaped relation between leptin levels and total mortality, with low and high levels being associated.
Leptin and incident CHF, CVD, and mortality

with greater mortality. Such a U-shaped relation has been described for BMI and mortality (23,24). Additional analyses confirmed that the U-shaped relation was largely driven by the association of lower and higher leptin levels with noncardiovascular mortality. It is conceivable that low and high leptin levels are a marker of greater risk of death due to noncardiovascular causes (such as cancer). Such an association would parallel the known association of both low and high BMI with noncardiovascular mortality, including that due to cancer (23,25). However, the association of leptin with mortality remained U-shaped after the analyses were restricted to individuals who survived the first year of follow-up, suggesting that the results are not confounded by greater mortality risk in individuals with comorbidities and low leptin levels.

Limitations
We must acknowledge the limitations of our approach. Leptin levels were determined on nonfasting blood samples, and diurnal variations in concentrations may result in random misclassification, which may have biased our results toward the null hypothesis of no association between leptin and the outcomes evaluated. Our data were obtained in an elderly sample of white individuals of European ancestry. Thus, the generalizability of our data to other age-groups or ethnicities is unknown.

In summary, we observed that leptin is associated positively with incident CHF and CVD. However, adjustment for BMI attenuated these associations, suggesting that leptin does not offer incremental prognostic information over BMI. The relationship of leptin with mortality was U-shaped. Additional studies are warranted to confirm our findings.

Acknowledgments—This work was supported through National Institutes of Health/National Heart, Lung, and Blood Institute Contracts N01-HC25195, N01-HV28178, K24-HL04334, and R01-DK080739. Contract N01-HC25195 funded the performance of examinations at which leptin levels were obtained. The other grants supported the interpretation of data and preparation of the manuscript.

No potential conflicts of interest relevant to this article were reported.

References
1. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS: Obesity and the risk of heart failure. N Engl J Med 347:305–313, 2002
2. Hubert HB, Feinleib M, McNamara PM, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67:968–977, 1983
3. Paolillo G, Tagliamonte MR, Galardeis M, Zito GA, Petrocelli A, Carella C, de Divitis O, Varricchio M: Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 34:1047–1052, 1999
4. Schafer K, Halle M, Goeschen C, Deltas C, Pynn M, Loskutoff DJ, Konstantinides M: Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 24:112–117, 2004
5. Bouloumie A, Marumo T, Lafontan M, Busse R: Leptin induces oxidative stress in human endothelial cells. FASEB J 13:1231–1238, 1999
6. Rajapurohitam V, Gan XT, Kirshenbaum LA, Karmazyn M: The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 93:277–279, 2002
7. Barouch LA, Berkowitz DE, Harrison RW, O’Donnell CP, Hare JM: Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108:754–759, 2003
8. Werner N, Nickenig G: From fat fighter to risk factor: the zigzag trek of leptin. Arterioscler Thromb Vasc Biol 24:7–9, 2004
9. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardenas G, Papapetropoulos A, Sessa WC, Majde LA, Schechner JS, Schwab MB, Polverini PJ, Flores-Riveros JR: Biological action of leptin as an angiogenic factor. Science 281:1683–1686, 1998
10. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N: Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 104:3052–3056, 2001
11. Couillard C, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorman SJ, Lupien PJ, Despres JP: Leptinemia is not a risk factor for ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Diabetes Care 21:782–786, 1998
12. Langenberg C, Bergstrom J, Laughlin GA, Barrett-Connor E: Ghrelin, adiponectin, and leptin do not predict long-term changes in weight and body mass index in older adults: longitudinal analysis of the Rancho Bernardo cohort. Am J Epidemiol 162:1189–1197, 2005
13. Dawber TR, Meadors GF, Moore FE Jr: Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health 41:279–281, 1951
14. Kannel WB, Wolf PA, Garrison R: Section 34. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements. In The Framingham Heart Study: An Epidemiological Investigation of Cardiovascular Disease. Kannel WB, Poll PA, Garrison RJ, Eds. Washington, DC, U.S. Govt. Printing Office, 1988 (NIH publ. no. 87-203)
15. Saad MF, Damani S, Gingerich RL, Riaad-Gabriel MG, Khan A, Boyadjian R, Jina-gouda SD, el Tawil K, Rude RK, Kamdar V: Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 82:579–584, 1997
16. Considine RV, Sinha MK, Heiman ML, Kriquet L, Winder DF, Smith U, Ohnesorg J, Gicquel B, Bauer T: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295, 1996
17. Schulze PC, Ratzsch J, Linke A, Schoene N, Adams V, Gielen S, Erbs S, Moeblus-Winkler S, Schuler G: Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 5:33–40, 2003
18. Leyva F, Anker SD, Egerer K, Stevenson JC, Kox WJ, Coats AJ: Hyperleptinemia in chronic heart failure: relationships with insulin. Eur Heart J 19:1547–1551, 1998
19. Nickola MW, Wold LE, Colligan PB, Wang GJ, Samson WK, Ren J: Leptin attenuates cardiac contraction in rat ventricular myocytes: role of NO. Hypertension 36:501–505, 2000
20. McGaffin KR, Sun CK, Rager JJ, Romano LC, Zou B, Mathier MA, O’Doherty RM, McTiernan CF, O’Donnell CP: Leptin signaling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury. Cardiovasc Res 77:54–63, 2008
21. Soderberg S, Ahren B, Jansson JH, John-son O, Hallmans G, Asplund K, Olsson T: Leptin is associated with increased risk of myocardial infarction. J Intern Med 264:408–418, 1999
22. Ring BD, Scully S, Davis CR, Baker MB, Cullen MJ, Pelleymouther MA, Danilenko DM: Systemically and topically administered leptin both accelerate wound healing in diabetic ob/ob mice. Endocrinology 146:446–449, 2000
23. Avons P, Dascametiere P, Rakotovao R: Weight and mortality. Lancet 1:1104, 1983
24. Rhoads GG, Kagan A: The relation of coro-nary disease, stroke, and mortality to weight in youth and in middle age. Lancet 1:492–495, 1983
25. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO: Overweight as an avoidable cause of cancer in Europe. Int J Cancer 91:421–430, 2001